Clene Inc. (CLNN)
NASDAQ: CLNN · Real-Time Price · USD
2.580
-0.500 (-16.23%)
At close: Apr 1, 2025, 4:00 PM
2.985
+0.405 (15.71%)
After-hours: Apr 1, 2025, 4:39 PM EDT
Clene Employees
As of December 31, 2023, Clene had 85 total employees, including 82 full-time and 3 part-time employees. The number of employees decreased by 1 or -1.16% compared to the previous year.
Employees
85
Change (1Y)
-1
Growth (1Y)
-1.16%
Revenue / Employee
$4,024
Profits / Employee
-$463,529
Market Cap
22.15M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 85 | -1 | -1.16% |
Dec 31, 2022 | 86 | -16 | -15.69% |
Dec 31, 2021 | 102 | 28 | 37.84% |
Dec 31, 2020 | 74 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Walmart | 2,100,000 |
PepsiCo | 319,000 |
Costco Wholesale | 316,000 |
Anheuser-Busch InBev | 143,885 |
Unilever | 120,040 |
The Procter & Gamble Company | 108,000 |
Mondelez International | 90,000 |
Philip Morris International | 83,100 |
CLNN News
- 8 hours ago - Clene to Present at the Jones Healthcare and Technology Innovation Conference - GlobeNewsWire
- 8 days ago - Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights - GlobeNewsWire
- 20 days ago - Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment - GlobeNewsWire
- 26 days ago - Clene to Present at the 37TH Annual Roth Conference - GlobeNewsWire
- 4 weeks ago - Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11 - Accesswire
- 5 weeks ago - Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction - GlobeNewsWire
- 4 months ago - FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS - GlobeNewsWire
- 6 months ago - Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules - GlobeNewsWire